Is it appropriate to combine tacrolimus Envarsus XR 4 mg once daily with tacrolimus immediate‑release Envarsus 1 mg three times daily?

This Regimen is Inappropriate and Potentially Dangerous

You should NOT combine Envarsus XR 4 mg once daily with additional Envarsus 1 mg tablets three times daily—this represents a fundamental misunderstanding of tacrolimus formulations and dosing principles. The FDA label explicitly states that Envarsus XR is an extended-release formulation designed for once-daily dosing only, and it is not interchangeable with immediate-release tacrolimus formulations 1.

Critical Problems with This Regimen

Formulation Confusion

• Envarsus XR is extended-release tacrolimus that releases medication over 24 hours and must be taken once daily
• There is no "Envarsus 1 mg immediate-release" product—you appear to be either:
  • Taking additional Envarsus XR tablets multiple times daily (incorrect), OR
  • Confusing Envarsus XR with immediate-release tacrolimus (Prograf or generic)
• The FDA explicitly warns that under- or overexposure to tacrolimus may result in graft rejection or serious adverse reactions 1

Dosing Error

Your current regimen totals 7 mg of tacrolimus daily (4 mg + 3 mg), which is:

• Administered incorrectly if using Envarsus XR multiple times daily
• Potentially toxic if you're inadvertently combining extended-release with immediate-release formulations
• Not following any established dosing protocol

What You Should Be Doing

For Kidney Transplant Recipients (Most Common)

Target tacrolimus trough levels should guide your dosing 2:

• First month post-transplant: 6-10 ng/mL
• Beyond first month: 4-8 ng/mL (monotherapy) or 3-5 ng/mL (with other immunosuppressants like mycophenolate)

Proper Envarsus XR dosing 1:

• Take once daily in the morning on an empty stomach
• Starting dose typically 0.14 mg/kg/day for de novo transplant
• If converting from immediate-release tacrolimus, use approximately 80% of the total daily immediate-release dose
• Adjust based on trough levels measured at least twice weekly initially

Immediate Action Required

1. Contact your transplant team immediately—do not adjust doses on your own
2. Get tacrolimus trough level checked urgently to assess current exposure
3. Clarify your actual medication:
   • Are all tablets Envarsus XR extended-release?
   • Or are you taking immediate-release tacrolimus (Prograf/generic) in addition?
4. Review proper administration:
   • Envarsus XR: once daily, morning, empty stomach
   • Immediate-release tacrolimus: twice daily, 12 hours apart

Therapeutic Drug Monitoring is Essential

The FDA mandates measuring tacrolimus whole blood trough concentrations 1:

• At least twice during the first week after any dose change
• Before the morning dose (trough level)
• Using validated assays (immunoassay or LC-MS/MS)
• Steady state achieved approximately 7 days after dose changes

Common Pitfalls to Avoid

Never mix formulations without supervision: Envarsus XR, Advagraf, and immediate-release tacrolimus are NOT interchangeable 3. Each has different pharmacokinetics and bioavailability.

Never take extended-release formulations multiple times daily: This defeats the purpose of the formulation and creates unpredictable drug exposure.

Never adjust immunosuppression independently: The narrow therapeutic index of tacrolimus means small changes can cause rejection (too low) or toxicity/infection (too high) 1.

Bottom Line

Your current regimen suggests either a prescribing error, dispensing error, or misunderstanding of instructions. Stop taking tacrolimus as currently prescribed and contact your transplant center today. Bring all medication bottles to clarify exactly what you have. Your transplant team needs to establish the correct formulation and dosing schedule based on your trough levels, time since transplant, and concurrent immunosuppression. Continuing this regimen risks either graft rejection from subtherapeutic levels or serious toxicity from excessive exposure.